- Home
- TPST vs DYAI Comparison
TPST vs DYAI Comparison
Compare TPST & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | DYAI |
|---|---|---|
| Founded | 2011 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 32.5M |
| IPO Year | 2012 | 2003 |
Fundamental Metrics
Financial Performance| Metric | TPST | DYAI |
|---|---|---|
| Price | $2.03 | $0.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $11.00 | $3.00 |
| AVG Volume (30 Days) | ★ 278.7K | 48.0K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $295,000.00 | ★ $3,090,345.00 |
| Revenue This Year | N/A | $122.79 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $0.65 |
| 52 Week High | $12.22 | $1.35 |
Technical Indicators
Market Signals| Indicator | TPST | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 47.00 |
| Support Level | $1.57 | $0.71 |
| Resistance Level | $2.48 | $0.99 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 67.59 | 38.92 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.